Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B

Young Eun Chon, Junyong Park, SangHoon Ahn, doyoung kim, KwangHyub Han, Chae Yoon Chon, Ara Choi, Seungup Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: In patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB) receiving adefovir (ADV) add-on LAM therapy, insufficient viral suppression or the appearance of additional ADV resistance has remained unresolved. This study determined the partial virological response (PVR) criteria to predict a virological response (VR) at week 96 in these patients. Methods: 96 patients with LAM-resistant CHB (ADV add-on LAM therapy >2 years) were analyzed. For predicting VR at week 96, the area under the receiver operating characteristic curve values at different time points were compared to establish the optimal time point, and the maximal Youden index was calculated to determine the optimal cut-off hepatitis B virus (HBV) DNA level. Results: 50 (52.1%) patients achieved VR at 2 years after ADV add-on LAM therapy. The optimal PVR criteria were determined to be HBV DNA 500 IU/ml at week 48. 44 (45.8%) patients who met optimal PVR criteria showed a significantly higher risk for detectable HBV DNA levels at week 96 than those with a favorable VR (HBV DNA <500 IU/ml) at week 48. Conclusions: This study suggested optimal PVR criteria in patients with LAM-resistant CHB receiving ADV add-on LAM therapy. Modification of the antiviral agent regimen should be considered if the serum HBV DNA level exceeds 500 IU/ml at week 48.

Original languageEnglish
Pages (from-to)196-203
Number of pages8
JournalDigestion
Volume87
Issue number3
DOIs
Publication statusPublished - 2013 Jun 1

Fingerprint

Lamivudine
Chronic Hepatitis B
Hepatitis B virus
DNA
Therapeutics
adefovir
ROC Curve
Antiviral Agents
Serum

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

@article{7daa8c060509458e856b44beb04cfd58,
title = "Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B",
abstract = "Background/Aims: In patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB) receiving adefovir (ADV) add-on LAM therapy, insufficient viral suppression or the appearance of additional ADV resistance has remained unresolved. This study determined the partial virological response (PVR) criteria to predict a virological response (VR) at week 96 in these patients. Methods: 96 patients with LAM-resistant CHB (ADV add-on LAM therapy >2 years) were analyzed. For predicting VR at week 96, the area under the receiver operating characteristic curve values at different time points were compared to establish the optimal time point, and the maximal Youden index was calculated to determine the optimal cut-off hepatitis B virus (HBV) DNA level. Results: 50 (52.1{\%}) patients achieved VR at 2 years after ADV add-on LAM therapy. The optimal PVR criteria were determined to be HBV DNA 500 IU/ml at week 48. 44 (45.8{\%}) patients who met optimal PVR criteria showed a significantly higher risk for detectable HBV DNA levels at week 96 than those with a favorable VR (HBV DNA <500 IU/ml) at week 48. Conclusions: This study suggested optimal PVR criteria in patients with LAM-resistant CHB receiving ADV add-on LAM therapy. Modification of the antiviral agent regimen should be considered if the serum HBV DNA level exceeds 500 IU/ml at week 48.",
author = "Chon, {Young Eun} and Junyong Park and SangHoon Ahn and doyoung kim and KwangHyub Han and Chon, {Chae Yoon} and Ara Choi and Seungup Kim",
year = "2013",
month = "6",
day = "1",
doi = "10.1159/000348853",
language = "English",
volume = "87",
pages = "196--203",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "3",

}

Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B. / Chon, Young Eun; Park, Junyong; Ahn, SangHoon; kim, doyoung; Han, KwangHyub; Chon, Chae Yoon; Choi, Ara; Kim, Seungup.

In: Digestion, Vol. 87, No. 3, 01.06.2013, p. 196-203.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B

AU - Chon, Young Eun

AU - Park, Junyong

AU - Ahn, SangHoon

AU - kim, doyoung

AU - Han, KwangHyub

AU - Chon, Chae Yoon

AU - Choi, Ara

AU - Kim, Seungup

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Background/Aims: In patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB) receiving adefovir (ADV) add-on LAM therapy, insufficient viral suppression or the appearance of additional ADV resistance has remained unresolved. This study determined the partial virological response (PVR) criteria to predict a virological response (VR) at week 96 in these patients. Methods: 96 patients with LAM-resistant CHB (ADV add-on LAM therapy >2 years) were analyzed. For predicting VR at week 96, the area under the receiver operating characteristic curve values at different time points were compared to establish the optimal time point, and the maximal Youden index was calculated to determine the optimal cut-off hepatitis B virus (HBV) DNA level. Results: 50 (52.1%) patients achieved VR at 2 years after ADV add-on LAM therapy. The optimal PVR criteria were determined to be HBV DNA 500 IU/ml at week 48. 44 (45.8%) patients who met optimal PVR criteria showed a significantly higher risk for detectable HBV DNA levels at week 96 than those with a favorable VR (HBV DNA <500 IU/ml) at week 48. Conclusions: This study suggested optimal PVR criteria in patients with LAM-resistant CHB receiving ADV add-on LAM therapy. Modification of the antiviral agent regimen should be considered if the serum HBV DNA level exceeds 500 IU/ml at week 48.

AB - Background/Aims: In patients with lamivudine (LAM)-resistant chronic hepatitis B (CHB) receiving adefovir (ADV) add-on LAM therapy, insufficient viral suppression or the appearance of additional ADV resistance has remained unresolved. This study determined the partial virological response (PVR) criteria to predict a virological response (VR) at week 96 in these patients. Methods: 96 patients with LAM-resistant CHB (ADV add-on LAM therapy >2 years) were analyzed. For predicting VR at week 96, the area under the receiver operating characteristic curve values at different time points were compared to establish the optimal time point, and the maximal Youden index was calculated to determine the optimal cut-off hepatitis B virus (HBV) DNA level. Results: 50 (52.1%) patients achieved VR at 2 years after ADV add-on LAM therapy. The optimal PVR criteria were determined to be HBV DNA 500 IU/ml at week 48. 44 (45.8%) patients who met optimal PVR criteria showed a significantly higher risk for detectable HBV DNA levels at week 96 than those with a favorable VR (HBV DNA <500 IU/ml) at week 48. Conclusions: This study suggested optimal PVR criteria in patients with LAM-resistant CHB receiving ADV add-on LAM therapy. Modification of the antiviral agent regimen should be considered if the serum HBV DNA level exceeds 500 IU/ml at week 48.

UR - http://www.scopus.com/inward/record.url?scp=84877861664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877861664&partnerID=8YFLogxK

U2 - 10.1159/000348853

DO - 10.1159/000348853

M3 - Article

C2 - 23689059

AN - SCOPUS:84877861664

VL - 87

SP - 196

EP - 203

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 3

ER -